Back to results
US 2014/0227314 A1Published application
Engineered Type IV Pilin of Clostridium difficile
AssigneeUniversity of Maryland, Baltimore
InventorMichael Donnenberg
Life of this patent
Estimating the term…
Abstract
The present invention relates to engineered Clostridium difficile type IV pilin (tfp) genes, type IV pilin proteins which can serve as a diagnostic marker for identification of patients infected with C. difficile, and vaccines comprising type IV pilin proteins, antigenic fragments and variants thereof for therapeutic interventions.
Claims12
A pharmaceutical composition for inducing an immune response against Clostridium difficile comprising an isolated C. difficile type IV pilin or an antigenic fragment or variant thereof, wherein the variant is recognized by an antibody that binds the C. difficile type IV pilin.
Dependencies are inferred from the claim text.